CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022
CohBar, Inc. (NASDAQ: CWBR) will release its 2021 fourth quarter and full year financial results on March 29, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CohBar, Inc. (NASDAQ: CWBR) will release its 2021 fourth quarter and full year financial results on March 29, 2022, after market close. A conference call and webcast is scheduled for 5:00 p.m. ET on the same day, providing updates on the company's business. Interested participants can access the call via dial-in or through the CohBar website. An audio replay will be available from 8:00 p.m. ET on March 29 until 11:59 p.m. ET on April 19, 2022.
Positive
- Upcoming release of fourth quarter and full year financial results may provide insights on performance.
- Hosting a conference call allows direct communication with investors.
Negative
- None.
Details
News Market Reaction – CWBR
The recorded move for CWBR in the trading session of this news was +2.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host conference call and webcast at 5:00 p.m. ET
MENLO PARK, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2021 fourth quarter and full year financial results after the market closes on Tuesday, March 29, 2022. Management will host a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company’s business.
Details for the Conference Call:
| Date: March 29, 2022 | |
| Time: 5:00 p.m. ET (2:00 p.m. PT) | |
| Conference Audio | |
| - | Dial-in U.S. and Canada: (877) 451-6152 |
| - | Dial-in International: (201) 389-0879 |
| - | Conference ID No.: 13726040 |
| Webcast | |
| - | A simultaneous webcast of the call will be accessible via the Investors section of the CohBar website at www.cohbar.com. |
For individuals participating in the Investor Call or webcast, please call or login to the conference audio approximately 10 minutes prior to its start.
An audio replay of the call will be available beginning at 8:00 p.m. Eastern Time on March 29, 2022, through 11:59 p.m. Eastern Time on April 19, 2022. To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 13726040. The audio recording will also be available at www.cohbar.com during the same period.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical-stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options. CohBar has assembled the leading position in exploring the mitochondrial genome and its utility for the development of novel therapeutics, including world-renowned expertise in mitochondrial biology, a broad intellectual property estate, key opinion leaders and disciplined drug discovery and development processes. CohBar is utilizing its Mito+ platform to identify and develop modified versions of natural peptides called analogs to treat a variety of serious conditions, with a focus on diseases involving inflammation and fibrosis.
For additional company information, please visit www.cohbar.com and engage with us on LinkedIn.
Contacts:
Jordyn Tarazi
Director of Investor Relations
CohBar, Inc.
(650) 445-4441
Jordyn.tarazi@cohbar.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.